Beatrix StelteLudwig - Vincerx Pharma Executive Officer
| VINC Stock | USD 0.28 0.02 7.69% |
Executive
Beatrix StelteLudwig is Executive Officer of Vincerx Pharma
| Address | 260 Sheridan Avenue, Palo Alto, CA, United States, 94306 |
| Phone | 650 800 6676 |
| Web | https://vincerx.com |
Vincerx Pharma Management Efficiency
The company has return on total asset (ROA) of (0.6599) % which means that it has lost $0.6599 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4245) %, meaning that it created substantial loss on money invested by shareholders. Vincerx Pharma's management efficiency ratios could be used to measure how well Vincerx Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -2.09. The current year's Return On Capital Employed is expected to grow to -3.21. At present, Vincerx Pharma's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.07, whereas Total Assets are forecasted to decline to about 17.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Anne DVM | Molecular Partners AG | N/A | |
| Ashraf Amanullah | Inhibrx | 56 | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Josep Garcia | Inhibrx | N/A | |
| Matteo MD | Cue Biopharma | 55 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| David MBA | Inhibrx | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Bonne MBA | Inhibrx | 47 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Carlos Bais | Inhibrx | N/A | |
| KerriAnn Millar | Cue Biopharma | 54 | |
| Charbel PharmD | Inhibrx | N/A | |
| Lucinda Warren | Cue Biopharma | N/A | |
| MD MBA | Molecular Partners AG | N/A | |
| Brendan Eckelman | Inhibrx | 45 | |
| Jeffrey Jensen | Inhibrx | N/A | |
Management Performance
| Return On Equity | -1.42 | ||||
| Return On Asset | -0.66 |
Vincerx Pharma Leadership Team
Elected by the shareholders, the Vincerx Pharma's board of directors comprises two types of representatives: Vincerx Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vincerx. The board's role is to monitor Vincerx Pharma's management team and ensure that shareholders' interests are well served. Vincerx Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vincerx Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Melissa SPHR, Director Culture | ||
| Ahmed MD, Chairman CoFounder | ||
| Raquel Izumi, President, CoFounder | ||
| Karen Quarford, Vice Compliance | ||
| Tom JD, General Founder | ||
| Raj MBA, VP Manufacturing | ||
| Karen MBA, Vice Compliance | ||
| John MD, Founder Board | ||
| Beatrix StelteLudwig, Executive Officer | ||
| HansGeorg Lerchen, Chief Officer | ||
| Steven RPh, Chief Officer | ||
| MBA MBA, Chief Officer | ||
| David MBA, Head Devel | ||
| Alexander MBA, Chief Officer | ||
| Gabriela Jairala, Sr Communications |
Vincerx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vincerx Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.42 | ||||
| Return On Asset | -0.66 | ||||
| Current Valuation | 411.76 K | ||||
| Shares Outstanding | 30.88 M | ||||
| Shares Owned By Insiders | 18.06 % | ||||
| Shares Owned By Institutions | 36.00 % | ||||
| Number Of Shares Shorted | 600.01 K | ||||
| Price To Book | 0.97 X | ||||
| EBITDA | (42.61 M) | ||||
| Net Income | (40.16 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vincerx Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vincerx Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vincerx Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vincerx Pharma Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vincerx Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vincerx Stock refer to our How to Trade Vincerx Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vincerx Pharma. If investors know Vincerx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vincerx Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.14) | Return On Assets (0.66) | Return On Equity (1.42) |
The market value of Vincerx Pharma is measured differently than its book value, which is the value of Vincerx that is recorded on the company's balance sheet. Investors also form their own opinion of Vincerx Pharma's value that differs from its market value or its book value, called intrinsic value, which is Vincerx Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vincerx Pharma's market value can be influenced by many factors that don't directly affect Vincerx Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vincerx Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vincerx Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vincerx Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.